Year All20242023202220212020201920182017201620152014 Dec 17, 2024 Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC Nov 27, 2024 Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference Nov 26, 2024 Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome Nov 14, 2024 Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 Nov 06, 2024 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results Oct 28, 2024 Soleno Therapeutics to Participate in Upcoming November Investor Conferences Oct 21, 2024 Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D. Oct 08, 2024 Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome Sep 16, 2024 Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference Aug 27, 2024 Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
Nov 26, 2024 Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
Nov 14, 2024 Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
Nov 06, 2024 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Oct 08, 2024 Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
Aug 27, 2024 Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome